التفاصيل البيبلوغرافية
| العنوان: |
Incidence of the V600K mutation amongmelanoma patients with BRAF mutations, andpotential therapeutic response to the specificBRAF inhibitor PLX4032. |
| المؤلفون: |
Rubinstein, Jill C., Sznol, Mario, Pavlick, Anna C., Ariyan, Stephan, Cheng, Elaine, Bacchiocchi, Antonella, Kluger, Harriet M., Narayan, Deepak, Halaban, Ruth |
| المصدر: |
Journal of Translational Medicine; 2010, Vol. 8, p67-69, 3p |
| مصطلحات موضوعية: |
MELANOMA, CANCER treatment, CLINICAL trials, GENETIC mutation, LETHAL mutations, PATIENTS |
| مستخلص: |
Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Translational Medicine is the property of BioMed Central and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder